2.Epidemiology and Clinical Course of Diabetic Nephropathy; Is There Any Differences in Prevalence and Incidence of Diabetic Nephropathy between Type 1 and Type 2 Diabetes Mellitus?.
Korean Journal of Nephrology 2005;24(6):865-871
No abstract available.
Diabetes Mellitus, Type 2*
;
Diabetic Nephropathies*
;
Epidemiology*
;
Incidence*
;
Prevalence*
3.Sleep Disorder and Cardiovascular Risk Factors in Type 2 Diabetes Mellitus.
The Korean Journal of Internal Medicine 2011;26(3):274-276
No abstract available.
Cardiovascular Diseases/*epidemiology
;
Diabetes Mellitus, Type 2/*epidemiology
;
Female
;
Humans
;
Male
;
Sleep Disorders/*epidemiology
4.Risk factors for schizophrenia patients with type 2 diabetes: a metaanalysis.
Min ZHOU ; Chuan XIAO ; Min YANG ; Ping YUAN ; Yuanyuan LIU
Journal of Central South University(Medical Sciences) 2015;40(3):241-249
OBJECTIVE:
To investigate risk factors for schizophrenia patients with complication of type 2 diabetes mellitus and to provide scientific evidence for prevention and management of this disease.
METHODS:
Relevant studies on schizophrenia with type 2 diabetes mellitus in China were searched through PubMed, Medline, CBM, CNKI and VIP from 1997 to 2014. Meta-analysis was performed using RevMan 5.2 soft ware.
RESULTS:
A total of 26 studies involving 6 373 participants (including 957 cases and 5 416 controls) were included. The results of Meta-analysis showed that the risk factors for schizophrenic patients with complication of type 2 diabetes mellitus were: gender (female) (OR=1.28, 95%CI: 1.09-1.50), age (≥ 40 year) (OR=6.02, 95%CI: 4.48-8.09), overweight (OR=2.32, 95%CI: 1.52-2.88), family history of diabetes (OR=6.12, 95%CI: 3.16-11.86), duration of schizophrenia (>10 years) (OR=3.60, 95%CI: 2.39-5.41), triglycerides (MD=0.38, 95%CI: 0.05-0.71).
CONCLUSION
Male, old age, overweight, family history of diabetes, longer duration and high level of triglycerides are risk factors for schizophrenic patients with complication of diabetes mellitus.
China
;
Diabetes Mellitus, Type 2
;
epidemiology
;
Female
;
Humans
;
Male
;
Overweight
;
epidemiology
;
Risk Factors
;
Schizophrenia
;
epidemiology
5.Childhood diabetes in India.
Annals of Pediatric Endocrinology & Metabolism 2018;23(3):126-130
This review describes the epidemiology of childhood diabetes in India. It focuses on the incidence and prevalence of type 1 diabetes and its complications and comorbid conditions. The review also covers data related to type 2 diabetes, glucose intolerance, and monogenic diabetes from India. A brief discussion regarding unique contributions from India to the world literature is included. The topics discussed include use of camel milk as adjuvant therapy in type 1 diabetes, relevance of the A1/A2 hypothesis, and comprehensive clinico-etiopathological classification of type 1 diabetes.
Camels
;
Child
;
Classification
;
Diabetes Mellitus, Type 1
;
Diabetes Mellitus, Type 2
;
Epidemiology
;
Glucose Intolerance
;
Humans
;
Incidence
;
India*
;
Milk
;
Prevalence
6.Associations between glycated hemoglobin and glucose indicators in adults in areas at different altitude in China.
Xiao ZHANG ; Mei ZHANG ; Chun LI ; Zheng Jing HUANG ; Meng Ting YU ; Li Min WANG
Chinese Journal of Epidemiology 2023;44(3):401-407
Objective: To explore the associations of glycated hemoglobin (HbA1c) with FPG and oral glucose tolerance test 2-hour (OGTT-2 h) in areas at different altitude in China. Methods: Subjects who participated in 2018-2019 China Chronic Disease and Risk Factor Surveillance and had no prior type 2 diabetes diagnosis were included. Subsequently, they were categorized into three groups based on altitude of living area (<2 000, 2 000- and ≥3 000 m). With adjustment for intracluster correlation, multivariable linear regression analysis was performed to evaluate the associations of HbA1c with FPG and OGTT-2 h in the context of HbA1c was normal (<5.7%) or abnormal (≥5.7%). Furthermore, the shape of relationships between HbA1c and glucose indicators was examined using restricted cubic spline. Finally, receiver operating characteristic curve was used to evaluate the diagnostic performance of HbA1c for diabetes. Results: A total of 157 277 subjects were included in the analysis. While FPG and OGTT-2 h levels gradually decreased with increase of altitude, HbA1c level was similar among the three groups. When HbA1c was <5.7%, its association with FPG and OGTT-2 h was weak and no obvious difference was observed among the three groups. When HbA1c was ≥5.7%, the FPG and OGTT-2 h increased by 15.45% (95%CI:14.71%- 16.18%) and 24.54% (95%CI:23.18%-25.91%) respectively per one standard deviation increase in HbA1c in group in area at altitude <2 000 m. However, the FPG and OGTT-2 h increased by 13.08% (95%CI:10.46%-15.76%) and 21.72% (95%CI:16.39%-27.31%), respectively, in group in area at altitude 2 000- m, and increased by 11.41% (95%CI:9.32%-13.53%) and 20.03% (95%CI:15.38%- 24.86%), respectively, in group of altitude ≥3 000 m. The restricted cubic spline indicated that the curve showing the association of HbA1c with FPG and OGTT-2 h was flat when HbA1c was <5.7%, but showed a positive linear relationship when HbA1c was ≥5.7%. The area under curve for detecting diabetes was 0.808 (95%CI:0.803-0.812) in group of altitude <2 000 m and 0.728 (95%CI:0.660-0.796, P=0.022) in group of altitude ≥3 000 m. The relevant optimal cutoff value of HbA1c was 5.7%, with a sensitivity of 65.4% and a specificity of 83.0%, and 6.0%, with a sensitivity of 48.3% and a specificity of 93.7%, respectively. Conclusions: When HbA1c was ≥5.7%, the association between HbA1c and glucose indicators became weaker as the increase of altitude. In the area at altitude ≥3 000 m, it may not be appropriate to use HbA1c in the diagnosis of diabetes.
Adult
;
Humans
;
Glycated Hemoglobin
;
Diabetes Mellitus, Type 2/diagnosis*
;
Blood Glucose/analysis*
;
Glucose
;
Altitude
;
Fasting
;
China/epidemiology*
;
Diabetes Mellitus/epidemiology*
8.The Combined Effect of Dyslipidemia on the Incidence of Type 2 Diabetes: A Prospective Cohort Study in Northwest of China.
Min Zhen WANG ; Tian DAI ; Shan ZHENG ; Cheng YU ; Miao XIA ; Hong Yan YANG ; De Sheng ZHANG ; Chun YIN ; Ya Fei JIN ; Ning CHENG ; Ya Na BAI
Biomedical and Environmental Sciences 2021;34(10):814-818
9.Advances in diabetic erectile dysfunction.
Shu-Yan HUANG ; Shu CHEN ; Yi-Ping FENG
National Journal of Andrology 2006;12(2):178-182
Erectile dysfunction is common complication of diabetes mellitus. The incidence of diabetes mellitus induced erectile dysfunction (DMED) is 20% - 75%. DMED appears to be due to vascular-neuropathic and corpus cavernosum smooth muscular damage. To control blood glucose, blood pressure and blood lipids is the basis of DMED therapy. In 50% of the patients with DMED, the phosphodiesterase 5 inhibitors is effective, while intracavernous pharmacotherapy is effective for more than 90%. Penile prosthesis implantation continues to be the treatment of choice in case of other therapy failure.
Animals
;
Diabetes Complications
;
epidemiology
;
Diabetes Mellitus, Type 2
;
epidemiology
;
Erectile Dysfunction
;
epidemiology
;
pathology
;
therapy
;
Humans
;
Male
;
Rabbits
;
Rats
10.Efficacies of Stem Cell Therapies for Functional Improvement of the β Cell in Patients with Diabetes: A Systematic Review of Controlled Clinical Trials
Gyudeok HWANG ; Hyunsuk JEONG ; Hae Kyung YANG ; Hun Sung KIM ; Hanter HONG ; Na Jin KIM ; Il Hoan OH ; Hyeon Woo YIM
International Journal of Stem Cells 2019;12(2):195-205
BACKGROUND AND OBJECTIVES: This study was performed to investigate whether stem cell therapy enhances β cell function by meta-analysis with proper consideration of variability of outcome measurements in controlled trial of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) patients. METHODS: A systematic search was performed from inception to January 2018 in PubMed, EMBASE, and Cochrane databases. β cell function was assessed by stimulated C-peptide, fasting C-peptide, normal glycosylated hemoglobin levels (HbA1C), and exogenous insulin dose patterns. The quality of the studies were assessed by both the Cochrane Collaboration's Risk of Bias (ROB) for Randomized controlled trials and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized controlled trials. RESULTS: From the selected final 15 articles, total of 16 trials were analyzed. There were 6 T1DM trials (total 153 cases) and 10 T2DM trials (total 457 cases). In T2DM patients, the changes in stimulated C-peptide, HbA1c, and exogenous insulin dose versus baseline showed a favorable pattern with a significant heterogeneity in stem cell therapy. In T1DM, there was no significant difference between control group and stem cell therapy group in three indicators except for HbA1c. Most of the studies were rated as having high risk of bias in the quality assessment. CONCLUSIONS: The stem cell therapy for DM patients is not effective in T1DM but seems to be effective in improving the β cell function in T2DM. However the observed effect should be interpreted with caution due to the significant heterogeneity and high risk of bias within the studies. Further verification through a rigorously designed study is warranted.
Bias (Epidemiology)
;
C-Peptide
;
Diabetes Mellitus
;
Diabetes Mellitus, Type 1
;
Diabetes Mellitus, Type 2
;
Fasting
;
Hemoglobin A, Glycosylated
;
Humans
;
Insulin
;
Population Characteristics
;
Stem Cells